KMT2A and acute lymphoblastic leukemia: CRISPR-Cas9 gene editing of primary human fetal liver (FL) CD34+ cells to produce a t(4;11)/MLL-AF4 translocation replicates the clinical features of infant-ALL in a xenograft model and drives infant-ALL- and fetal-specific molecular programs.